Myth
8 horas hace
Thanks, and the TA said he can't disclose it, seems odd since they post it every week.
Anyway this is from 3/18, add the 310 ml issued on 6/18 that and add the new 105 it doesn't seem to add up. Unless abround 100 mjl came off restriction at some time....
Authorized Shares
3,000,000,000
03/18/2024
Outstanding Shares
1,600,576,407
03/18/2024
Restricted
329,292,017
03/18/2024
SLC-JD
8 horas hace
No - and it's not saved at archive.org.
However, per the Q3 report, they had 1,910,576,407 outstanding (including the 310,000,000 shares issued on June 18), so I'd imagine that increase in total outstanding means that they've since issued another 105,000,000 restricted shares (since any new issuance will be restricted).
SLC-JD
1 día hace
The silence is deafening.
alternately:
In the absence of a narrative, one will be provided for you.
With tinfoil hat securely in place, I'm beginning to wonder if the absence of updates is intentional. Is it possible that there are discussions with a potential suitor to acquire a controlling interest, but due to the fact that a portion of those shares must be acquired on the market, the offer is contingent upon keeping PPS depressed?
I hate to be this paranoid, but I really cannot understand why this company and it's current leadership team is so grossly negligent in providing the updates/taking the steps necessary to maximize shareholder value. The erosion in PPS over the past 12 mos (to say nothing of the precipitous drop since 2021) and the profound lack of response by the company makes me seriously question whether they are intentionally playing a role in the prolonged downturn.
Management: Over the years, you have expressed an interest in running a public company because of the benefits you perceived...It's well past time for you to fulfill your obligations.
Myth
1 semana hace
SOHM, Inc.
@sohminc
We are excited to announce that our Walmart Marketplace store is now live and ready for you to shop! You can find our products here:
https://walmart.com/search?q=SOHM+ADDS+LIFE+TO+LIVES&facet=brand:SOHM+ADDS+LIFE+TO+LIVES
As we continue to grow, we are adding more OTC, cosmeceutical, and nutraceutical products to our Walmart and Amazon stores. Stay tuned for the launch of our e-commerce website, which is coming soon!
More updates are coming.....
$SHMN
hardlesson
2 semanas hace
It's been 13 weeks since this: "Successfully Negotiating with top 10 Pharma Giants" Announcement: 93 days. "We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks."
____
Maybe the successful negotiation turned unsuccessful?
Maybe they meant to say months? But it has been 3 months too?
Is their clock broke?
hardlesson
2 semanas hace
Baron/David, How many days has it been since:
Last PR? 86 days: https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announce-Dr-Wei-Zhu-Onboard-as-Senior-Marketing-and-Sales-Consultant?id=459809
"We are very excited to have her on board, and her experience in the biotech field will enhance our reach to wider opportunities in the coming days/weeks."
Japan patent touting "licenses and partnerings" ? 90 days : https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announces-Allowances-Of-Japanese-Patent-Claims-Received-from-Japans-Patent-Office--Tokkyoch-JPO-Protecting-Tran?id=459158
David Zarling "Marketing talent" announcement? 115 days : https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-Announce-Dr-David-Zarling-Onboard-as-Senior-Product-Development-Advisor?id=456478
ABBIE prelaunch announcement? 5 months. https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-has-Received-ABBIE-Technology-Kits-Pre-Launch-Pre-Orders?id=453974
"We are confident that these pre-launch and further orders will continue to bring us new dimensions, new opportunities and new avenues for our technology in the coming days."
"Momentum Tweet Video?" 45 days.
Europe and Korea: "We will be releasing additional information regarding our position in Europe and Korea in the near future."
Walmart.com Approval Tweet? 50 days. "We are glad to share that the company has received approval from Walmart Marketplace to sell our products on its platform. In the next few days as we progress, we will start putting our products on it."
"Successfully Negotiating with top 10 Pharma Giants" Announcement: 93 days. "We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks."
Carlsbad passed inspection: 4 months: "This achievement allows us to pursue various state wholesale licenses in the coming weeks proactively. Additionally, we are in the process of registering our products with various state and federal programs and formularies."
_____
Much more could be added...but the point is made...
Myth
3 semanas hace
Hey JD, I was wondering what you meant here, were you referring to ABBIE revenue ?
I expect to see a penny plus if the annual/Q1 reports show revenue, and hope for a nickel
I assumed you were and have to ask, don't you expect the co to make an announcement when there is an actual sale or license deal ?
I guess my point is this, imo we don't have to wait until the annual or first qtr filing, I would highly doubt either will show ABBIE revenue that we will not be expecting due to a PR pre filing......
SLC-JD
3 semanas hace
Until they demonstrate that they can or cannot deliver there's no reason for anything to happen outside of a few flippers playing in the margins.
We're seeing the result of years of bullshit announcements with no meaningful action.
IMHO, the best thing they could do is 1) release their annual report ahead of schedule, and 2) release a substantive earnings projection for the next quarter and FY regardless of whether it's positive, neutral, or negative (and keep doing so on a quarterly basis)...you know, like real companies do.
Until SHMN can demonstrate that they are willing to be honest and forthright, there's no reason for any shareholders/prospective investors to act on anything they say.
hardlesson
1 mes hace
To your points SLCJD: Advancements in Cell and Gene Therapies
"The momentum behind cell and gene therapies continues to gain steam, particularly with exciting developments in treating conditions like type 1 diabetes. Recently, for example, Sana Biotechnology announced promising data in one patient in a first-in-human allogeneic cell therapy for type 1 diabetes — without immunosuppression.
And Bayer, together with our subsidiary BlueRock Therapeutics, announced plans to initiate a Phase III trial for its allogeneic investigational cell therapy for Parkinson’s disease, based on compelling data from the Phase I trial.
These examples, among others, are creating high hopes for cell and gene therapies, as they begin to demonstrate positive human data."
5 Insights From The 2025 JP Morgan Healthcare Conference
https://www.forbes.com/sites/juergeneckhardt/2025/01/16/5-insights-from-the-2025-jp-morgan-healthcare-conference/
And: An Increase In Dealmaking Activity
"One of the most notable trends is the resurgence of dealmaking in the pharmaceutical sector. In 2024, we saw 106 biotech venture deals exceeding $100 million, signaling a bounce back from previous downturns. The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent cliff for many drug developers. With an estimated $400 billion in revenue losses expected from patent expirations between now and 2033, the urgency to refill pipelines is great. This year, I predict we will witness an uptick in both early and late-stage asset acquisitions, like Eli Lilly’s acquisition of Scorpion Therapeutics, as companies look to secure innovative therapies that can make a significant impact on patient care. That said, the larger financing sizes will also be tied to ensuring companies pass critical testing milestones."
And taking a look backward:
Coastar Therapeutics to Present in JP Morgan Conference Events
SAN DIEGO, January 5, 2023 – Coastar Therapeutics Inc., a biotechnology company developing novel delivery technologies to supercharge cell and gene therapies, announced that it will be presenting at events of the 42nd JP Morgan Healthcare Conference, January 8-11 in San Francisco.
Coastar’s innovative cell membrane coating technology platform enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease targets. The technology can lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.
“We are truly excited to be presenting during the JP Morgan week of events.” said Eddie Y. Chung, CEO of Coastar Therapeutics, “In the past 12 months, the Coastar team has made tremendous progress in developing our erythrocyte membrane based gene delivery platform. From local injection to systemic delivery, from viral to non-viral payloads, from oncology to gene therapy, we are generating important data and achieved great levels of efficacy and precision in delivery. I look forward to meeting and sharing our progress with colleagues and partners at JPM.”
“JPM is the week of premier events where the entire industry convenes and deals are made,” said Dr. Chongyang Luo, Chief Operating Officer of Coastar, “We are excited to meet up with our current and prospective partners. The industry realizes that effective and targeted gene delivery is a bottleneck to better and cost-effective therapies. Coastar is on track to break the bottleneck and supercharge cell and gene therapy.”
ABOUT COASTAR THERAPEUTICS
Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnSTM and eLNPTM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully targeted to tumor or other disease sites. The company is working with a number of global partners to help deliver their drugs.
SOHM, Inc. and Coastar Therapeutics Sign MoU and Announce Collaboration to Revolutionize Genome Editing Using Red Blood Cell Membrane Derived Carriers
https://www.otcmarkets.com/stock/SHMN/news/SOHM-Inc-and-Coastar-Therapeutics-Sign-MoU-and-Announce-Collaboration-to-Revolutionize-Genome-Editing-Using-Red-Blood-Ce?id=435326
https://x.com/sohminc/status/1874344120971587899
https://x.com/sohminc/status/1856048539803230341
"We are pleased to share that the company is successfully negotiating with a diverse range of companies, from the top 10 pharmaceutical giants to small private firms, regarding the ABBIE kits. Detailed information will be provided once we finalize the contracts, sales, delivery methods, and purposes, which we anticipate will occur in the coming weeks.
The interest and attention our breakthrough gene editing technology has garnered, particularly in its application for drug development, is truly gratifying. We continue to explore new opportunities and are organizing several lunch-and-learn sessions throughout the fourth quarter to prepare for revenue growth in 2025."
____
That was Nov 11, 2024. 10 weeks ago. We are overdue, imo.